These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30521971)

  • 21. Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report.
    Yazaki T; Kimoto M; Minagawa A; Maruno T; Yamanaka M; Sonehara K; Hama M; Nakamura T; Kanda S; Hanaoka M; Hachiya T
    Am J Case Rep; 2024 Jun; 25():e943466. PubMed ID: 38822519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
    Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Ninomaru T; Hata A; Hara S; Komatsu M
    Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.
    Liu Y
    Cancer Biol Ther; 2018 Jun; 19(6):445-449. PubMed ID: 29461911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
    J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
    Takeuchi S; Yano S
    Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
    Zhang X; Maity TK; Ross KE; Qi Y; Cultraro CM; Bahta M; Pitts S; Keswani M; Gao S; Nguyen KDP; Cowart J; Kirkali F; Wu C; Guha U
    Cancer Res; 2021 Jun; 81(11):3051-3066. PubMed ID: 33727228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
    Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
    Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
    Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
    Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination.
    Kuo MH; Lee AC; Hsiao SH; Lin SE; Chiu YF; Yang LH; Yu CC; Chiou SH; Huang HN; Ko JC; Chou YT
    Cancer Res; 2020 Oct; 80(20):4426-4438. PubMed ID: 32816907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.
    Zhao J; Shao J; Zhao R; Li R; Yu K; Zhu L; Zhang J
    Thorac Cancer; 2018 Jan; 9(1):129-135. PubMed ID: 29120087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.